MatriSys Bioscience focuses on the $142 Billion worldwide dermatology and skin care market by developing microbiome-derived therapies for the top dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections which have a huge impact on 230 million patients’ quality of life.
Meet MatriSys Bioscience, Inc.
Why is your company the best option to solve the problem you're solving?
Atopic dermatitis affects up to a third of pediatrics. We believe that our non-steroidal, non-immune suppressing therapeutic will be the leader in this very large market. Our atopic dermatitis candidate is Phase 2 ready. We have reviewed and approved our development plan with FDA.
What nuggets of info make you interesting? Why do people care about what you're doing?
We are the only product in development for atopic dermatitis that isn't steroidal and immune system blocking. We address the cause of atopic dermatitis - staph. Aureus colonization.
What else do you want us to know?
Following our atopic dermatitis play, we are also developing therapies for Acne, Rosacea, Skin Cancer, and Netherton's Syndrome (an orphan indication).
BEHIND THE COMPANY
Founder/CEO: Mark Wilson
What is your company's secret sauce?
We know how to make room-temperature stable biotherapeutics from these skin microbiome discoveries. Product development is in house.
What inspired you (CEO/Founder) to start/run this company?
I have spent 30 years in biopharmaceutical development. I combined the incredible skin microbiome skin science of UCSD's Richard Gallo with an experienced biopharma development team. Our therapeutics are going to revolutionize the field of skin therapeutics.
What's the best entrepreneurial advice you've received?
Take the money... don't worry about the dilution. The pie will get bigger.
What's the worst entrepreneurial advice you've received?
Don't worry about the board's executive sessions...
What sets your company culture apart?
Bold and flexible. We have brand new science (Skin Microbiome) and a completely novel approach for our first candidate MSB-01 (killing colonized staph. Aureus). The rewards are a whole new class of biotherapeutics.